3 results
The primary objective of this phase III study is to demonstrate that lixisenatide can reduce cardiovascularmorbidity and mortality (composite endpoint of cardiovascular (CV) death, non-fatal myocardialinfarction (MI), non-fatal stroke,…
Main study:Primary objective: What are the long-term effects (i.e. after 8-week drug exposure) of the GLP-1RA versus a single dose prandial insulin onrenal hemodynamics (glomerular filtration rate/ effective renal plasma flow in basal insulin-…
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…